Alzheimer's Disease Clinical Trial
Official title:
Usability of Virtual Reality in Subjects With Mild Cognitive Impairment or Alzheimer's Disease. MeMO-RV2
Cognitive and memory problems characterize Alzheimer's disease (AD). Along with these
disorders, psychological and behavioral symptoms (also known as neuropsychiatric symptoms) ,
as well as pathophysiological processes are frequently found and involved significantly in
maintaining autonomy, prognosis and treatment of the disease. Apathy or disorder motivation
is the most common disorder behavior and early stages of cognitive impairment. Apathy is
particularly associated with cognitive difficulties such as attention deficit disorder -
concentration.
In terms of prevention as term care , there is now a broad consensus that interventions on
cognition and behavior must not be limited to pharmacological treatment but should also
promote non-drug approaches.
Interest in video games (serious games and serious games) as intervention support
rehabilitation is growing. Similarly, the virtual reality (VR) and the new information
technologies and communications offer significant opportunities in terms of rehabilitation
and therapeutic assistance.
This protocol is part of a European project to propose techniques for improving the
treatment of people at risk of social exclusion ( VERVE project ) aims .
A first experiment conducted in 2013 showed the acceptability of Virtual Reality (VR) in
healthy elderly subjects. In a second step , it is important to validate the feasibility of
using the RV or in frail subjects with mild cognitive impairment or Alzheimer's disease in
mild to moderate in a clinical environment.
This is a biomedical , randomized given to a group of patients with mild cognitive
impairment or Alzheimer's disease & diseases associated with mild to moderate.
n/a
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
| Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
| Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
| Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
| Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
| Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
| Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
| Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
| Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
| Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
| Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
| Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
| Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
| Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
| Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
| Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
| Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
| Not yet recruiting |
NCT01940952 -
Zydena on Cognitive Function of Alzheimer's Disease Patients
|
Phase 3 |